GHRH vs GHRP: How the Two Growth Hormone Peptide Classes Differ

Order forms for pituitary research often list sermorelin, tesamorelin, CJC-1295 and ipamorelin side by side, as if they were four strengths of one tool. The GHRH vs GHRP split says otherwise. Two separate receptor families sit behind those names, with different G proteins, different second messengers and different sensitivities to the rest of the endocrine circuit. A lab that plans assays or buys comparator sets without keeping the two apart can end up with a well-run experiment that answers the wrong question.

Two receptor families behind one catalogue heading

The compounds sort cleanly once you ask which receptor they were designed for:

• GHRH analogs mimic growth hormone-releasing hormone, the hypothalamic peptide that acts on the GHRH receptor of anterior pituitary somatotrophs. Sermorelin, CJC-1295 and tesamorelin belong here.
• GHRP-type secretagogues act on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for the stomach-derived hormone ghrelin. The synthetic growth hormone-releasing peptides, such as GHRP-6, GHRP-2 and hexarelin, and the more selective ipamorelin, belong here.

Both families end at the same cell, the somatotroph, and both lead to growth hormone release in animal and cell models. Almost everything else about them differs.

The GHRH receptor: Gs, cAMP and a fragile N-terminus

The GHRH receptor is a class B1 GPCR. Its large extracellular domain grips the C-terminal part of the peptide ligand, while the ligand’s N-terminus reaches into the transmembrane bundle to switch the receptor on. The receptor couples mainly to Gs, so activation raises cAMP and engages protein kinase A. That route promotes both release of stored hormone and transcription of the growth hormone gene, which means the response is limited by how much the somatotroph can make.

The N-terminus that activates the receptor is also its weak spot. Dipeptidyl peptidase-4 (DPP-4) clips native GHRH between residues 2 and 3, and in vitro work in plasma by Frohman and colleagues in 1989 identified this cut as the inactivating step. Each practical analog answers that problem differently:

• Sermorelin is the native 1-29 fragment with a C-terminal amide, the shortest sequence that keeps full receptor activity. It has no special protection against DPP-4.
• CJC-1295 combines amino acid substitutions with, in its DAC form, a reactive group that bonds to cysteine 34 of albumin, as described by Jetté and colleagues in 2005. Our note on the DAC and non-DAC forms covers the chemistry.
• Tesamorelin has its N-terminal tyrosine acylated with a trans-3-hexenoyl group, which blocks the cleavage site without making the molecule depend on albumin. See our piece on tesamorelin as a stabilised analog.

The GHRP side: GHS-R1a, calcium and constant background signal

GHS-R1a is a class A GPCR, built around a compact binding pocket inside the transmembrane helices rather than a large external capture domain. It couples mainly to Gq/11, driving phospholipase C, inositol trisphosphate formation and a rise in intracellular calcium, which triggers exocytosis of stored hormone granules.

Two properties make this receptor unusual for a lab:

1. High constitutive activity. GHS-R1a signals noticeably with no ligand bound. Basal signalling therefore has to be measured, and inverse agonists, which push activity below that baseline, are a real pharmacological class here rather than a textbook curiosity.
2. A history of off-target axes. Early secretagogues raised ACTH, cortisol and prolactin alongside growth hormone in animal models. When Raun and colleagues described ipamorelin in 1998, the point of interest was growth hormone release in rat and pig models without that accompanying ACTH and cortisol rise. “Selective” in this literature means exactly that, not selectivity across receptor subtypes in the usual sense. Our article on ipamorelin and GHS-R1a goes further.

GHRH vs GHRP at a glance

One practical consequence follows directly from the second messenger row. Run a GHS-R1a compound through a cAMP assay and it can look inactive. That is a mismatch between assay and receptor, not evidence that the material is faulty.

Where the two pathways meet

Somatostatin tone

Somatostatin receptors on somatotrophs couple to Gi and pull cAMP down, so they oppose GHRH receptor signalling head-on. Secretagogue signalling travels mainly by the calcium route, so somatostatin restrains it less fully. In an intact animal this is one of the clearest ways to tell the classes apart. In dispersed pituitary cells, which have lost their hypothalamic input, the difference largely vanishes, and that alone explains many disagreements between cell and whole-animal results.

Combined responses

Because the two classes use separate receptors and separate messengers on the same cell, pairing them in preclinical models gives a larger response than either one, often described as synergy. That makes a handy classification tool: an unknown compound that adds to a known GHRH analog but not to a known secretagogue is probably acting at GHS-R1a, and the reverse pattern points to the GHRH receptor.

Pulse pattern versus total exposure

Growth hormone is released in pulses, and continuous receptor occupancy desensitises both receptors: kinases phosphorylate them, arrestins bind, and the receptors are pulled inside the cell. An albumin-bound, long-lived analog is therefore not just a longer version of a short one; it changes the exposure pattern. A study must say whether compounds were matched on peak concentration or total exposure, since the two designs can give opposite-looking answers.

Choosing preparations and readouts

• Receptor-level assays: cAMP for the GHRH receptor; calcium flux or inositol phosphate accumulation for GHS-R1a, with basal activity measured in the same run.
• Dispersed pituitary cells in culture: the usual bench assay for hormone release, bearing in mind that somatostatin tone is missing.
• Perifusion: cells or tissue fragments under continuous flow, allowing timed exposure and washout when kinetics matter.
• Animal sampling: frequent serial samples are needed to capture pulses; a single time point mostly reflects the sampling schedule.
• IGF-1: a steady integrated readout of sustained growth hormone exposure that cannot distinguish a pulsed pattern from a continuous one.

Albumin-binding analogs need one more precaution. In serum-containing media part of the compound is bound to albumin, so it appears less potent than in serum-free conditions. Comparing a conjugated and an unconjugated analog in serum therefore understates the conjugated one.

Buying comparator sets for a two-class study

A study that includes both families usually needs several compounds at once, which suits a single consolidated order. A few points keep the comparison fair:

1. Request each compound from one lot for the full study, and record lot and vial numbers against each experiment in your inventory log.
2. Check HPLC purity with the gradient and column stated, since deletion sequences one residue shorter can hide under a shallow gradient.
3. Confirm identity by mass against the calculated value, remembering to include any acyl or conjugate group in the arithmetic.
4. Normalise stock concentrations to net peptide content rather than vial weight, because counter-ions and water can shift apparent potency by a margin similar to the effects being compared.

Bulk Peptides products are third-party tested for HPLC purity, certificates are published for some products, and vials are matched to their certificate by cap and crimp colour. Both families are listed in our growth hormone secretagogue range, and with mix-and-match volume pricing every vial in a mixed comparator order counts toward the break. For naming conventions such as GRF(1-29), see our sermorelin reference note.

The compounds discussed here are sold strictly for in-vitro laboratory research. They are not for human or veterinary use, and the findings described come from cell and animal studies only.